Metastatic castration-resistant prostate is an advanced form of the cancer that’s incurable. Learn about treatment options ...

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

Medically reviewed by Matthew Wosnitzer, MD Castration-resistant prostate cancer (CRPC) is a type of advanced prostate cancer ...

Metastatic castration-resistant prostate cancer (mCRPC) treatment can involves chemotherapy, radiation, and more. Find the ...

The phase 2a LEGION-100 trial seeks to evaluate the safety and effectiveness of the SYNC-T/SV-102 combination therapy for treating metastatic castration-resistant prostate cancer (mCRPC) and to ...

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

This is the first trial to prospectively demonstrate the impact of bone-protecting agents use on fracture risk for men receiving an androgen receptor pathway inhibitor.

The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GBq of 67 Cu-SAR-bisPSMA.This follows the recent ...